ESR1 and breast cancer: Therefore, in a quest for a better cost-effective approach, researchers proposed the selection of various surrogate IHC markers namely cyclin D1, claudin-1, and epidermal growth factor receptor (EGFR) for prognosis of breast cancer patients, supplementing the traditional ER, PR, and HER2/neu receptor (6).